Revolutionizing Cancer Detection with
The True Liquid Biopsy

Transforming Early Cancer Detection with AI/ML and Non-Invasive Urine Testing

Removing Barriers to Early Cancer Detection

Millions of lives are lost due to late cancer diagnoses each year.

In 2022 alone, 20 million new cancer cases and 9.7 million cancer-related deaths were reported worldwide.¹ Without intervention, cases could rise to 35 million annually by 2050.²

Early detection saves lives, but invasive procedures, delayed results, and limited access continue to stand in the way.³

PanGIA Biotech is committed to overcoming these challenges—with integrity and excellence—to redefine cancer detection.

What if early-stage cancers could be detected and distinguished—when treatment is most effective—using a non-invasive urine specimen?

A Smarter, Simpler Solution for Cancer Detection

Traditional diagnostics often rely on blood draws or biopsies.
PanGIA Biotech offers a non-invasive, AI-powered alternative that uses urine.

Patients and clinicians would overwhelmingly prefer a quick, non-invasive test with superior sensitivity and specificity.

Reduce Unnecessary Biopsies

Improve Diagnostic Yield

Reduce Costs

Fewer Complications and Side Effects

PanGIA combines a machine learning algorithm with proprietary unbiased binding of small molecules, proteins, and cells, followed by a signal readout and final analysis, creating a biomolecular profile of the patient.

The PanGIA Platform

True Liquid Biopsy Pipeline

PanGIA Prostate

PanGIA Breast

PanGIA Ovarian

PanGIA Lung

PanGIA Renal

PanGIA Bladder

PanGIA Colorectal

PanGIA Stomach

PanGIA Pancreas

PanGIA Liver

PanGIA Brain

& more!

Disruptive Innovation Use Case

The PanGIA Platform

PanGIA is a white space, urine based, non-invasive, machine learning driven, biomolecular profile testing platform.

Value to Patients

→ Improved predictive profile over PSA / other screening tests
→ Avoidance or warranted delay of invasive procedures

Value to Clinicians

→ Additional data points for identifying candidates for biopsies
→ Improved outcomes from missing fewer cancers and reduced side effects

Value to Payers

→ Avoidance of unnecessary biopsies
→ Avoidance of costs for side effects

References:

  1. World Health Organization. Global cancer burden growing amidst mounting need for services. Published February 1, 2024. Accessed December 28, 2024. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services
  2. American Cancer Society. Global cancer statistics 2024. Pressroom. Published February 1, 2024. Accessed December 28, 2024. https://pressroom.cancer.org/GlobalCancerStatistics2024
  3. World Health Organization. Cancer screening and early detection of cancer. Accessed December 28, 2024. https://www.who.int/europe/news-room/fact-sheets/item/cancer-screening-and-early-detection-of-cancer
  4. PanGIA Biotech. Internal Data. February 2023
  5. Lim FB, Lei T, Fernandez G, et al. A colorimetric chemical tongue detects and distinguishes between multiple analytes. Analyst. 2022;147(23):5283-5292. doi:10.1039/d2an01615j.
  6. Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8(9):e73076. doi:10.1371/journal.pone.0073076.